Related references
Note: Only part of the references are listed.The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
Erik J. M. van Bommel et al.
KIDNEY INTERNATIONAL (2020)
Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study
Carina Iskander et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies
Jie Liu et al.
DIABETES & VASCULAR DISEASE RESEARCH (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging
Kengo Kidokoro et al.
CIRCULATION (2019)
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendan L. Neuen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
George Grunberger et al.
DIABETES THERAPY (2018)
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
George Grunberger et al.
DIABETES THERAPY (2018)
Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes
Petter Bjornstad et al.
DIABETES CARE (2018)
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
David Z. I. Cherney et al.
KIDNEY INTERNATIONAL (2018)
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Christopher P. Cannon et al.
AMERICAN HEART JOURNAL (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
V. Sahasrabudhe et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z. I. Cherney et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials
Yuliya Lytvyn et al.
CIRCULATION (2017)
Urinary adenosine excretion in type 1 diabetes
Harindra Rajasekeran et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2017)
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
David Cherney et al.
DIABETOLOGIA (2016)
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
Paola Fioretto et al.
DIABETOLOGIA (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Marko Skrtic et al.
DIABETOLOGIA (2014)
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
Josef Coresh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Is Doubling of Serum Creatinine a Valid Clinical 'Hard' Endpoint in Clinical Nephrology Trials?
H. J. Lambers Heerspink et al.
NEPHRON CLINICAL PRACTICE (2011)
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2006)
Share Paper
